(Reuters) – A commonly used asthma treatment could cut the need to hospitalize COVID-19 patients if the medicine is given within seven days of symptoms appearing, British researchers said on Tuesday.
Budesonide, sold under the brand name Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung, reduced the time needed for patients to recover from COVID-19 as well when given in the inhaled form, the University of Oxford said. (https://bit.ly/3q40g1W)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)
